BMRN BioMarin Pharmaceutical Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 6, 2026BMRN Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
BMRN Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Acerca de BioMarin Pharmaceutical Inc. - Common Stock Descripción general de la empresa de Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | BMRN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | 146.6promedio 5A ≈11.8 | ≈11.8 | · | · | |
| P/S (TTM) | 3.2promedio 5A ≈6.7 | ≈6.7 | 20.4 | Infravalorado | |
| P/C (MRQ) | 1.8promedio 5A ≈3.2 | ≈3.2 | 11.3 | Infravalorado | |
| Precio / FCF (TTM) | 15.0promedio 5A ≈152.1 | ≈152.1 | · | · | |
| Precio / Flujo de Caja (TTM) | 12.9promedio 5A ≈62.6 | ≈62.6 | · | · | |
| Precio / Valor Contable Tangible (MRQ) | 7.7promedio 5A ≈3.5 | ≈3.5 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | BMRN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | 4.4%promedio 5A ≈7.8% | ≈7.8% | -30.6% | De primer nivel | |
| Margen EBITDA (TTM) | 8.9%promedio 5A ≈12.0% | ≈12.0% | -30.6% | De primer nivel | |
| Margen antes de impuestos (TTM) | 4.4%promedio 5A ≈9.0% | ≈9.0% | -29.3% | De primer nivel | |
| Margen de Beneficio Neto (TTM) | 2.1%promedio 5A ≈7.2% | ≈7.2% | -29.6% | De primer nivel | |
| ROA (TTM) | 0.76%promedio 5A ≈2.9% | ≈2.9% | -22.9% | De primer nivel | |
| ROE (TTM) | 1.2%promedio 5A ≈3.7% | ≈3.7% | 18.1% | Débil | |
| ROIC | 4.9%promedio 5A ≈3.2% | ≈3.2% | 14.3% | Débil |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | BMRN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Deuda / Patrimonio (MRQ) | 0.7 | · | 0.3 | Deuda alta | |
| Ratio corriente (MRQ) | 2.4promedio 5A ≈4.4 | ≈4.4 | 3.2 | Baja liquidez | |
| Quick Ratio (Ratio Rápido) | 2.9promedio 5A ≈2.1 | ≈2.1 | 1.8 | Baja liquidez | |
| Deuda a Largo Plazo / Patrimonio (MRQ) | 0.6 | · | 0.6 | En línea |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | BMRN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 12.9%promedio 5A ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | 15.4%promedio 5A ≈13.4% | ≈13.4% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | 11.6% | · | · | · | |
| EPS YoY (EPS interanual) | -18.6%promedio 5A ≈50.5% | ≈50.5% | · | · | |
| Net Income YoY (Beneficio Neto interanual) | -18.3%promedio 5A ≈51.6% | ≈51.6% | · | · | |
| EPS CAGR 3Y (CAGR BPA 3A) | 33.9% | · | · | · | |
| EPS CAGR 5Y (CAGR BPA 5A) | -16.7% | · | · | · | |
| Net Income CAGR 3Y (CAGR Beneficio Neto 3A) | 35.1% | · | · | · | |
| Net Income CAGR 5Y (CAGR Beneficio Neto 5A) | -16.4% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | BMRN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.4promedio 5A ≈0.4 | ≈0.4 | 0.4 | En línea | |
| Inventory Turnover (Rotación de Inventario) | 0.6promedio 5A ≈0.6 | ≈0.6 | 1.0 | Por debajo del promedio | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 4.1promedio 5A ≈4.5 | ≈4.5 | 5.1 | Débil | |
| Revenue / Employee (Ingresos / Empleado) | ≈$1.0M | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 3, 2026 | $0.73 | $0.70 | 4.0% |
| 31 de marzo de 2026 | $0.54 | $0.77 | -29.5% | |
| 31 de diciembre de 2025 | $-0.24 | $0.64 | -137.7% | |
| 30 de septiembre de 2025 | $-0.16 | $0.38 | -142.2% | |
| 30 de junio de 2025 | $1.23 | $0.85 | 44.4% | |
| 31 de marzo de 2025 | $0.95 | $0.72 | 31.5% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $31.65 | $29.66 | $26.25 | $24.71 | $23.22 | $22.59 | $17.36 | $16.65 | $15.97 | $16.02 | $14.86 | $10.25 | |
| Revenue / Share | $16.32 | $14.51 | $12.63 | $11.09 | $10.10 | $9.71 | $9.52 | $8.41 | $7.53 | $6.72 | · | · | |
| Cash Flow / Share | $4.19 | $2.91 | $0.83 | $0.93 | $1.67 | $0.45 | $0.27 | $0.11 | $-0.05 | $-1.37 | · | · | |
| Cash / Share | $6.82 | $4.94 | $4.00 | $3.89 | $3.19 | $3.57 | $2.43 | $2.77 | $3.40 | $2.37 | $2.46 | $5.87 | |
| EPS (TTM) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | · | 192,032,000 | 191,907,000 | 190,967,000 | · | 190,429,000 | 190,114,000 | 188,866,000 | · | 188,219,000 | 187,948,000 | 186,667,000 | · | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | · | 192,032,000 | 197,091,000 | 196,474,000 | · | 197,147,000 | 200,505,000 | 199,262,000 | · | 191,173,000 | 194,998,000 | 194,363,000 | · | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | · |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | · | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | · | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | · | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | · | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | · | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | · | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | · | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | · | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | · |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.66 | $32.14 | · | $31.53 | $31.39 | $30.21 | · | $28.41 | $27.77 | $26.74 | · | $26.00 | $25.42 | $24.83 | · | · | |
| Revenue / Share | $5.09 | $3.88 | · | $4.04 | $4.19 | $3.79 | · | $3.78 | $3.55 | $3.26 | · | $3.04 | $3.05 | $3.07 | · | · | |
| Cash Flow / Share | · | $1.12 | · | · | · | $0.89 | · | · | · | $0.24 | · | · | · | $-0.38 | · | · | |
| Cash / Share | $4.52 | $11.50 | · | $6.51 | $6.32 | $5.47 | · | $3.54 | $5.11 | $3.94 | · | $4.17 | $3.69 | $3.09 | · | · | |
| EPS (TTM) | $0.39 | $1.39 | · | $2.67 | $3.38 | $2.70 | · | $1.66 | $1.32 | $1.06 | · | $0.78 | $0.53 | $0.39 | · | $0.43 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.41B | $3.24B | · | $3.09B | $3.06B | $2.95B | · | $2.75B | $2.59B | $2.47B | · | $2.31B | $2.23B | $2.17B | · | $2.01B | |
| Net Income TTM | $73M | $269M | · | $520M | $657M | $524M | · | $322M | $257M | $205M | · | $147M | $100M | $72M | · | $84M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | · | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 146.7 | 40.6 | · | 20.3 | 16.3 | 26.2 | · | 42.3 | 62.4 | 82.4 | · | 113.4 | 163.5 | 249.3 | · | 197.1 | |
| P/S | 3.3 | 3.4 | · | 3.4 | 3.4 | 4.6 | · | 4.9 | 6.1 | 6.7 | · | 7.2 | 7.3 | 8.4 | · | · | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | · | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| EV / Revenue | 4.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.68% | 2.5% | · | 4.9% | 6.2% | 3.8% | · | 2.4% | 1.6% | 1.2% | · | 0.88% | 0.61% | 0.40% | · | 0.51% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Margen Operativo % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Beneficio neto | $349M | $427M | $168M | $142M | $-64M |
| EPS Diluido | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Ratio Rápido | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $725M | $487M | $63M | $55M | $209M |
Propietarios institucionales (13F) 614 declarantes · $12.2B total · A fecha de 30 de septiembre de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 89 (-16 vs trimestre anterior) | 75 (+10 vs trimestre anterior) | 209 (+1 vs trimestre anterior) | 198 (+29 vs trimestre anterior) | +10.2M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $1 169 875 004 | 20 445 212 | 9,56% | Acciones |
| VANGUARD GROUP INC | $1 077 337 946 | 18 127 847 | 8,80% | Acciones |
| Dodge & Cox | $849 426 895 | 14 844 930 | 6,94% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $811 962 329 | 14 190 183 | 6,63% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $500 310 680 | 8 743 633 | 4,09% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494 877 355 | 8 648 678 | 4,04% | Acciones |
| NORGES BANK | $469 659 128 | 8 207 954 | 3,84% | Acciones |
| STATE STREET CORP | $446 370 874 | 7 800 959 | 3,65% | Acciones |
| VIKING GLOBAL INVESTORS LP | $435 819 735 | 7 616 563 | 3,56% | Acciones |
| Vestal Point Capital, LP | $344 750 500 | 6 025 000 | 2,82% | Acciones |
| AQR CAPITAL MANAGEMENT LLC | $322 537 038 | 5 699 541 | 2,64% | Acciones |
| FMR LLC | $275 965 970 | 4 822 893 | 2,26% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $233 217 034 | 4 075 714 | 1,91% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $223 885 722 | 3 911 794 | 1,83% | Acciones |
| Capital Research Global Investors | $200 521 024 | 3 504 387 | 1,64% | Acciones |
| Deep Track Capital, LP | $189 254 063 | 3 307 481 | 1,55% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $118 549 312 | 2 071 816 | 0,97% | Acciones |
| Assenagon Asset Management S.A. | $100 826 561 | 1 762 086 | 0,82% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $92 468 664 | 1 616 020 | 0,76% | Acciones |
| FIRST TRUST ADVISORS LP | $91 910 897 | 1 606 273 | 0,75% | Acciones |
| NORTHERN TRUST CORP | $89 154 711 | 1 558 104 | 0,73% | Acciones |
| MORGAN STANLEY | $86 115 553 | 1 504 989 | 0,70% | Acciones |
| Jones Hill Capital LP | $81 915 580 | 1 431 590 | 0,67% | Acciones |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76 264 876 | 1 332 836 | 0,62% | Acciones |
| Swedbank AB | $75 232 112 | 1 314 787 | 0,61% | Acciones |
| UBS Group AG | $73 613 817 | 1 286 505 | 0,60% | Acciones |
| DNB Asset Management AS | $72 566 061 | 1 268 194 | 0,59% | Acciones |
| Caisse de depot et placement du Quebec | $70 749 440 | 1 236 446 | 0,58% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $70 030 356 | 1 223 879 | 0,57% | Acciones |
| GOLDMAN SACHS GROUP INC | $68 777 119 | 1 201 977 | 0,56% | Acciones |
| AMERIPRISE FINANCIAL INC | $66 255 506 | 1 157 865 | 0,54% | Acciones |
| Bank of New York Mellon Corp | $66 106 543 | 1 155 305 | 0,54% | Acciones |
| CITADEL ADVISORS LLC | $64 224 186 | 1 122 408 | 0,52% | Acciones |
| Balyasny Asset Management L.P. | $60 344 956 | 1 054 613 | 0,49% | Acciones |
| ARGA Investment Management, LP | $59 474 983 | 1 039 409 | 0,49% | Acciones |
| Brandywine Global Investment Management, LLC | $56 211 687 | 945 847 | 0,46% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54 484 884 | 952 200 | 0,45% | Opción de compra |
| FRANKLIN RESOURCES INC | $53 560 439 | 936 044 | 0,44% | Acciones |
| MACKENZIE FINANCIAL CORP | $53 321 258 | 931 864 | 0,44% | Acciones |
| JANUS HENDERSON GROUP PLC | $48 409 915 | 857 010 | 0,40% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $48 062 765 | 850 819 | 0,39% | Acciones |
| Hudson Bay Capital Management LP | $47 206 614 | 825 002 | 0,39% | Acciones |
| Russell Investments Group, Ltd. | $44 813 913 | 783 148 | 0,37% | Acciones |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40 949 264 | 715 646 | 0,33% | Acciones |
| LOOMIS SAYLES & CO L P | $40 835 454 | 713 657 | 0,33% | Acciones |
| JPMORGAN CHASE & CO | $40 573 267 | 694 550 | 0,33% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39 869 980 | 696 784 | 0,33% | Acciones |
| Nuveen, LLC | $39 432 077 | 689 131 | 0,32% | Acciones |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39 311 857 | 687 030 | 0,32% | Acciones |
| Palo Alto Investors LP | $39 068 500 | 682 777 | 0,32% | Acciones |
Activistas y propietarios del %+ 5 4 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 presentaciones | 2 de febrero de 2015 | · | Presentación inicial | · | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 presentaciones | 31 de julio de 2009 | · | Presentación inicial | · | SEC |
| 6 de junio de 2005 | · | Presentación inicial | Campaña de la junta directiva | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 presentaciones | 6 de mayo de 2005 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 50 insiders · 21 directivos · 30 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 de marzo de 2026 F | 214 635 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 2 de mayo de 2005 A | 14 934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 6 de mayo de 2004 P | 79 285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 de marzo de 2026 F | 123 314 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 30 de abril de 2019 A | 47 686 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 de mayo de 2012 M | 41 089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 de septiembre de 2024 F | 185 074 | 0 | 0 | $0 |
| Robert Baffi | President, Global Mfg/Tech Ops | 20 de marzo de 2020 F | 117 138 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 30 de septiembre de 2026 F | 47 732 | 0 | 2 | $-558 646 |
| George Eric Davis | EVP, Chief Legal Officer | 2 de septiembre de 2026 S | 61 003 | 0 | 2 | $-2 762 781 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 de mayo de 2026 F | 42 472 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 de marzo de 2026 F | 84 140 | 0 | 1 | $-996 744 |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | 20 de enero de 2026 A | 25 610 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 de mayo de 2025 S | 14 173 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 2 de mayo de 2024 S | 66 767 | 0 | 0 | $0 |
| Andrea Acosta | GVP, Chief Accounting Officer | 16 de julio de 2021 F | 18 122 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 2 de julio de 2012 M | 59 030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 2 de marzo de 2009 M | 39 621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 7 de julio de 2008 A | 12 000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 1 de diciembre de 2005 M | 295 176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 de octubre de 2004 A | 2 740 | 0 | 0 | $0 |
| Robert M Plenge | Consejero | 10 de septiembre de 2026 A | 6 140 | 0 | 0 | $0 |
| Elizabeth M Anderson | Consejero | 2 de junio de 2026 A | 41 940 | 0 | 0 | $0 |
| Barbara W. Bodem | Consejero | 2 de junio de 2026 A | 21 045 | 0 | 0 | $0 |
| Maykin Ho | Consejero | 2 de junio de 2026 A | 35 500 | 0 | 0 | $0 |
| Mark J Enyedy | Consejero | 2 de junio de 2026 A | 21 040 | 0 | 0 | $0 |
| Athena Countouriotis | Consejero | 2 de junio de 2026 A | 21 040 | 0 | 0 | $0 |
| Robert J. Hombach | Consejero | 2 de junio de 2026 A | 49 360 | 0 | 0 | $0 |
| Timothy P Walbert | Consejero | 2 de junio de 2026 A | 17 270 | 0 | 0 | $0 |
| Ian T Clark | Consejero | 2 de junio de 2026 A | 14 490 | 0 | 0 | $0 |
| Willard H Dere | Consejero | 2 de junio de 2026 A | 46 440 | 0 | 0 | $0 |
| Richard A Meier | Consejero | 20 de mayo de 2025 A | 127 426 | 0 | 0 | $0 |
| Elaine J Heron | Consejero | 3 de junio de 2024 M | 97 720 | 0 | 0 | $0 |
| David E I Pyott | Consejero | 21 de mayo de 2024 A | 49 750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Consejero | 20 de mayo de 2024 F | 473 792 | 0 | 0 | $0 |
| Dennis Slamon | Consejero | 18 de marzo de 2024 M | 31 299 | 0 | 0 | $0 |
| Mark J Alles | Consejero | 23 de mayo de 2023 A | 15 095 | 0 | 0 | $0 |
| Bryan V Lawlis | Consejero | 23 de mayo de 2023 A | 33 140 | 0 | 0 | $0 |
| Michael G Grey | Consejero | 5 de marzo de 2021 M | 42 840 | 0 | 0 | $0 |
| Alan Lewis | Consejero | 4 de junio de 2019 A | 25 590 | 0 | 0 | $0 |
| Kathryn E Falberg | Consejero | 15 de julio de 2016 A | 2 640 | 0 | 0 | $0 |
| William D Young | Consejero | 10 de junio de 2015 A | 11 875 | 0 | 0 | $0 |
| Kenneth Bate | Consejero | 10 de junio de 2015 A | 11 875 | 0 | 0 | $0 |
| Pierre Lapalme | Consejero | 10 de junio de 2015 A | 31 250 | 0 | 0 | $0 |
| Joseph Klein III | Consejero | 8 de marzo de 2010 S | 35 000 | 0 | 0 | $0 |
| Franz L Cristiani | Consejero | 14 de junio de 2006 A | · | 0 | 0 | $0 |
| Erich Sager | Consejero | 24 de febrero de 2006 M | 3 309 | 0 | 0 | $0 |
| Gwynn Williams | Consejero | 30 de noviembre de 2004 A | 812 565 | 0 | 0 | $0 |
| John Urquhart | Consejero | 28 de julio de 2004 A | · | 0 | 0 | $0 |
| Mark Wood | · | 22 de mayo de 2013 M | 20 277 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 81 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,51% | 177 471 SH | 1 de octubre de 2026 | Diario |
| BBP · ETFis Series Trust I | 1,48% | 24 255 NS | 31 de julio de 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,31% | 15 080 NS | 31 de julio de 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,17% | 41 384 NS | 31 de julio de 2026 | N-PORT |
| RNIN · EA Series Trust | 1,15% | 35 050 NS | 31 de julio de 2026 | N-PORT |
| IBB · iShares Trust | 0,92% | 1 454 497 SH | 11 de septiembre de 2026 | Diario |
| CALF · Pacer Funds Trust | 0,79% | 482 285 NS | 31 de julio de 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,76% | 30 936 NS | 31 de julio de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,76% | 13 701 SH | 1 de octubre de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,73% | 60 076 NS | 31 de julio de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,44% | 77 415 NS | 31 de julio de 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,44% | 24 133 NS | 31 de julio de 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,38% | 26 065 SH | 1 de octubre de 2026 | Diario |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108 709 SH | 19 de agosto de 2026 | Diario |
| PTMC · Pacer Funds Trust | 0,33% | 21 272 NS | 31 de julio de 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,32% | 436 803 NS | 31 de julio de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2 559 860 SH | 19 de agosto de 2026 | Diario |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312 378 SH | 19 de agosto de 2026 | Diario |
| BKMC · BNY Mellon ETF Trust | 0,28% | 29 895 NS | 31 de julio de 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71 381 SH | 19 de agosto de 2026 | Diario |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,25% | 84 704 NS | 31 de julio de 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,25% | 2 838 NS | 31 de julio de 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,20% | 821 NS | 31 de julio de 2026 | N-PORT |
| IYH · iShares Trust | 0,20% | 111 984 SH | 11 de septiembre de 2026 | Diario |
| SMMD · iShares Trust | 0,17% | 102 244 SH | 11 de septiembre de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,17% | 16 041 NS | 31 de julio de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19 998 SH | 19 de agosto de 2026 | Diario |
| DFAS · Dimensional ETF Trust | 0,16% | 401 829 NS | 31 de julio de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,15% | 84 531 NS | 31 de julio de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,15% | 534 462 SH | 19 de agosto de 2026 | Diario |
| ISCG · iShares Trust | 0,15% | 21 366 SH | 11 de septiembre de 2026 | Diario |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20 990 SH | 19 de agosto de 2026 | Diario |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,13% | 28 086 SH | 1 de octubre de 2026 | Diario |
| ESML · iShares Trust | 0,13% | 56 252 SH | 11 de septiembre de 2026 | Diario |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4 433 137 SH | 19 de agosto de 2026 | Diario |
| IWS · iShares Trust | 0,12% | 286 469 SH | 11 de septiembre de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,12% | 2 217 617 SH | 19 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,11% | 11 104 SH | 11 de septiembre de 2026 | Diario |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3 901 NS | 31 de julio de 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0,09% | 797 NS | 31 de julio de 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 787 222 SH | 11 de septiembre de 2026 | Diario |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 11 519 SH | 1 de octubre de 2026 | Diario |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 18 000 NS | 31 de julio de 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 5 934 NS | 31 de julio de 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,06% | 143 957 NS | 31 de julio de 2026 | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0,05% | 212 NS | 31 de julio de 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,05% | 41 047 SH | 1 de octubre de 2026 | Diario |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 4 814 NS | 31 de julio de 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,05% | 18 819 NS | 31 de julio de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,04% | 347 063 NS | 31 de julio de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,03% | 19 135 NS | 31 de julio de 2026 | N-PORT |
| IWD · iShares Trust | 0,03% | 425 477 SH | 11 de septiembre de 2026 | Diario |
| DSI · iShares Trust | 0,03% | 27 701 SH | 11 de septiembre de 2026 | Diario |
| REVS · Columbia ETF Trust I | 0,03% | 1 740 NS | 31 de julio de 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 115 700 SH | 19 de agosto de 2026 | Diario |
| DFUV · Dimensional ETF Trust | 0,03% | 74 321 NS | 31 de julio de 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 45 172 SH | 1 de octubre de 2026 | Diario |
| TILT · FlexShares Trust | 0,03% | 9 322 NS | 31 de julio de 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,02% | 3 375 NS | 31 de julio de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 44 514 NS | 31 de julio de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 6 143 206 SH | 19 de agosto de 2026 | Diario |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 31 861 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 16 031 SH | 19 de agosto de 2026 | Diario |
| ESGV · VANGUARD WORLD FUND | 0,02% | 43 345 SH | 19 de agosto de 2026 | Diario |
| IUSG · iShares Trust | 0,02% | 97 914 SH | 11 de septiembre de 2026 | Diario |
| IWB · iShares Trust | 0,02% | 130 403 SH | 11 de septiembre de 2026 | Diario |
| IYY · iShares Trust | 0,02% | 8 059 SH | 11 de septiembre de 2026 | Diario |
| ITOT · iShares Trust | 0,02% | 253 576 SH | 11 de septiembre de 2026 | Diario |
| IUSV · iShares Trust | 0,02% | 71 403 SH | 11 de septiembre de 2026 | Diario |
| RECS · Columbia ETF Trust I | 0,02% | 16 398 NS | 31 de julio de 2026 | N-PORT |
| IWV · iShares Trust | 0,02% | 51 240 SH | 11 de septiembre de 2026 | Diario |
| DFUS · Dimensional ETF Trust | 0,02% | 53 858 NS | 31 de julio de 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 169 270 SH | 19 de agosto de 2026 | Diario |
| DFLV · Dimensional ETF Trust | 0,00% | 1 028 NS | 31 de julio de 2026 | N-PORT |
| IJH · iShares Trust | · | 6 782 201 SH | 11 de septiembre de 2026 | Diario |
| IJK · iShares Trust | · | 638 802 SH | 11 de septiembre de 2026 | Diario |
| IJJ · iShares Trust | · | 423 789 SH | 21 de agosto de 2026 | Diario |
| XJH · iShares Trust | · | 26 404 SH | 8 de septiembre de 2026 | Diario |
| ISCB · iShares Trust | · | 8 699 SH | 11 de septiembre de 2026 | Diario |
| ISCV · iShares Trust | · | 27 848 SH | 11 de septiembre de 2026 | Diario |
| SMMV · iShares Trust | · | 29 688 SH | 19 de agosto de 2026 | Diario |
BMRN Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
Precio objetivo a 12 meses
26 analistas · 2026-10-02Objetivo medio $91.62 +60,2%
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
| IBRX | $2.00B | -5.2 | 668.3% | -310.2% | 71.0% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
Últimas noticias Noticias recientes que mencionan a esta empresa
Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa
Ninguna señal abierta en este momento — ninguna tarjeta está completada, y eso es honesto.
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.